Literature DB >> 9870800

Association of mutations in the core promoter and precore region of hepatitis virus with fulminant and severe acute hepatitis in Japan.

T Aritomi1, H Yatsuhashi, T Fujino, K Yamasaki, O Inoue, M Koga, Y Kato, M Yano.   

Abstract

It was recently reported that mutations in the precore and core promoter region of hepatitis B virus (HBV) are associated with fulminant hepatitis. The aim of this study was to investigate the association of mutations in the precore and core promoter region of HBV with fulminant and severe acute hepatitis. We studied Japanese patients with acute HBV infection, including seven patients with fulminant hepatitis, 12 with severe acute hepatitis and 41 with acute self-limited hepatitis. The presence of HBV mutants was examined by using a point mutation assay to detect a G to A transition at position 1896 in the precore region and an A to T transition at position 1762 and a G to A transition at position 1764 in the core promoter region. Significant differences in the proportion of mutations in the precore or core promoter region were present between patients with fulminant hepatitis and self-limited acute hepatitis (7/7 (100%) vs 4/41 (9.8%), P<0.01) and between severe acute hepatitis and self-limited acute hepatitis (6/12 (50.0%) vs 4/41 (9.8%), P<0.01). The frequency of mutation increased proportionately with the severity of disease in patients with acute HBV infection. Fulminant hepatitis B in Japan is closely associated with mutations in the core promoter and precore gene of HBV. Point mutation assays for HBV precore and core promoter analysis may be useful to predict the outcome of liver disease in patients with acute HBV infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9870800     DOI: 10.1111/j.1440-1746.1998.tb00588.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  10 in total

1.  Early mutation of precore (A1896) region prior to core promoter region mutation leads to decrease of HBV replication and remission of hepatic inflammation.

Authors:  Y Karino; J Toyota; T Sato; T Ohmura; K Yamazaki; T Suga; K Nakamura; M Sugawara; T Matsushima; K Hino
Journal:  Dig Dis Sci       Date:  2000-11       Impact factor: 3.199

2.  A long-term follow-up analysis of serial core promoter and precore sequences in Japanese patients chronically infected by hepatitis B virus.

Authors:  Y Kajiya; K Hamasaki; K Nakata; S Miyazoe; Y Takeda; S Higashi; K Ohkubo; T Ichikawa; K Nakao; Y Kato; K Eguchi
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

3.  Hepatitis B virus genomes of chronic hepatitis patients do not contain specific mutations related to acute exacerbation.

Authors:  W Li; H Ikematsu; T K Yamaji; Y Chong; J Hayashi; S Kashiwagi
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

4.  Mutations of pre-core and basal core promoter before and after hepatitis B e antigen seroconversion.

Authors:  Nozomi Kamijo; Akihiro Matsumoto; Takeji Umemura; Soichiro Shibata; Yuki Ichikawa; Takefumi Kimura; Michiharu Komatsu; Eiji Tanaka
Journal:  World J Gastroenterol       Date:  2015-01-14       Impact factor: 5.742

Review 5.  New perspective on the natural course of chronic HBV infection.

Authors:  Yong-Yuan Zhang; Ke-Qin Hu; Zhongping Duan
Journal:  Front Med       Date:  2014-05-29       Impact factor: 4.592

6.  Adding interferon to lamivudine enhances the early virologic response and reversion of the precore mutation in difficult-to-treat HBV infection.

Authors:  Nobukazu Yuki; Takayuki Nagaoka; Kazuhiko Nukui; Masao Omura; Kazumasa Hikiji; Michio Kato
Journal:  J Gastroenterol       Date:  2008-07-04       Impact factor: 7.527

7.  The loss of HBeAg without precore mutation results in lower HBV DNA levels and ALT levels in chronic hepatitis B virus infection.

Authors:  Naoto Kawabe; Senju Hashimoto; Masao Harata; Yoshifumi Nitta; Michihito Murao; Takuji Nakano; Hiroaki Shimazaki; Yuko Arima; Naruomi Komura; Kyoko Kobayashi; Kentaro Yoshioka
Journal:  J Gastroenterol       Date:  2009-05-09       Impact factor: 7.527

8.  Efficacy and tolerability of Entecavir for hepatitis B virus infection after hematopoietic stem cell transplantation.

Authors:  Jun Aoki; Kiminori Kimura; Kazuhiko Kakihana; Kazuteru Ohashi; Hisashi Sakamaki
Journal:  Springerplus       Date:  2014-08-20

9.  Toll-like receptor-2 exacerbates murine acute viral hepatitis.

Authors:  Christian Bleau; Mélanie Burnette; Aveline Filliol; Claire Piquet-Pellorce; Michel Samson; Lucie Lamontagne
Journal:  Immunology       Date:  2016-08-10       Impact factor: 7.397

10.  Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response.

Authors:  Milan J Sonneveld; Roeland Zoutendijk; Hajo J Flink; Louwerens Zwang; Bettina E Hansen; Harry L A Janssen
Journal:  Clin Infect Dis       Date:  2012-10-05       Impact factor: 9.079

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.